Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens
Rattachement africain : de, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Rapid antimicrobial drug administration is crucial for the efficient treatment of sepsis or septic shock, but empirical therapy is limited by the increasing prevalence of multidrug-resistant bacteria. Thus, rapid and reliable antimicrobial susceptibility testing (AST) is needed to start appropriate antimicrobial drug administration as quickly as possible. In the present study, we evaluated the performance of the Reveal rapid AST system. From February to April 2021, 102 positive blood culture bottles (BCBs) from hospitalized patients with bacteremia caused by Gram-negative bacteria were included in the study. All isolates were tested by the Reveal system directly from the positive BCBs in comparison to the DxM MicroScan WalkAway. Essential agreement (EA) and category agreement (CA) were high with 98.5% and 97.1%, respectively. We also determined the susceptibility of 10 highly resistant CDC & FDA AR strains in duplicate. Here, EA was 99.6% and CA 97.9%. The average time to result by Reveal was 5.4 h ± 1.2 h compared to an average of 16 h by DxM MicroScan WalkAway for clinical strains and 3.8 h ± 1.2 h for more resistant CDC & FDA AR strains. Susceptibility determination with the Reveal rapid AST system directly from positive BCBs is for the frequently represented bug-drug combinations a reliable and accurate approach, meeting the European ISO guideline for the performance of AST systems. Moreover, AST directly from blood cultures performed with the Reveal system saves time when compared to the conventional AST, as no subculturing is needed and time to result is very short.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens
- Date Crossref
- 11/12/2024
- Éditeur
- American Society for Microbiology
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Laboratory Dr. Wisplinghoff pays non établi dans la noticeStructure de recherche
-
University of Cologne Institute for Medical Microbiology pays non établi dans la noticeUniversité ou école supérieure
-
Institute of Medical Microbiology and Hygiene pays non établi dans la noticeStructure de recherche
-
Specific Technologies (United States) pays non établi dans la noticeEntreprise
-
Specifica (United States) pays non établi dans la noticeEntreprise
-
Longevity Biotech (United States) pays non établi dans la noticeEntreprise
-
Human Longevity (United States) pays non établi dans la noticeEntreprise
-
Witten/Herdecke University Institute for Virology and Medical Microbiology pays non établi dans la noticeUniversité ou école supérieure
-
Wisplinghoff Laboratories pays non établi dans la noticeInstitution
-
Specific Diagnostics pays non établi dans la noticeInstitution
-
Cellular Longevity pays non établi dans la noticeOrganisation à but non lucratif
Laboratory Dr. Wisplinghoff, Institute for Medical Microbiology — University of Cologne et Institute of Medical Microbiology and Hygiene, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.